CN1079400A - 抗肿瘤方法和抗肿瘤剂 - Google Patents

抗肿瘤方法和抗肿瘤剂 Download PDF

Info

Publication number
CN1079400A
CN1079400A CN93103844A CN93103844A CN1079400A CN 1079400 A CN1079400 A CN 1079400A CN 93103844 A CN93103844 A CN 93103844A CN 93103844 A CN93103844 A CN 93103844A CN 1079400 A CN1079400 A CN 1079400A
Authority
CN
China
Prior art keywords
cell
antigen
mice
lymphocyte
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93103844A
Other languages
English (en)
Chinese (zh)
Inventor
江川滉二
佐藤一英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIO DEFENCE INSTITUTE Co Ltd
Original Assignee
BIO DEFENCE INSTITUTE Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIO DEFENCE INSTITUTE Co Ltd filed Critical BIO DEFENCE INSTITUTE Co Ltd
Publication of CN1079400A publication Critical patent/CN1079400A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN93103844A 1992-03-05 1993-03-05 抗肿瘤方法和抗肿瘤剂 Pending CN1079400A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP48840/92 1992-03-05
JP4048840A JPH05246889A (ja) 1992-03-05 1992-03-05 制癌方法および制癌剤

Publications (1)

Publication Number Publication Date
CN1079400A true CN1079400A (zh) 1993-12-15

Family

ID=12814449

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93103844A Pending CN1079400A (zh) 1992-03-05 1993-03-05 抗肿瘤方法和抗肿瘤剂

Country Status (15)

Country Link
EP (1) EP0563627A2 (2)
JP (1) JPH05246889A (2)
KR (1) KR930019225A (2)
CN (1) CN1079400A (2)
AU (1) AU3398793A (2)
BR (1) BR9300764A (2)
CA (1) CA2090957A1 (2)
CZ (1) CZ34293A3 (2)
FI (1) FI930976A7 (2)
HU (1) HUT67859A (2)
IL (1) IL104944A0 (2)
NO (1) NO930798L (2)
NZ (1) NZ247057A (2)
SK (1) SK15993A3 (2)
ZA (1) ZA931558B (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1110556C (zh) * 1993-03-26 2003-06-04 路德维格癌症研究所 编码肿瘤排斥抗原前体mage－3的分离的核酸分子及其应用
CN100381173C (zh) * 2003-03-04 2008-04-16 格林维尔医院系统公司 包含靶向部分和触发免疫反应部分的抗肿瘤剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1274592B (it) * 1994-08-05 1997-07-18 Angela Turiano Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
CA2275141A1 (en) * 1996-10-29 1998-05-07 Thomas Spies Cell stress regulated human mhc class i gene
FR2775189B1 (fr) * 1998-07-24 2001-06-08 Commissariat Energie Atomique Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g
ES2224603T3 (es) * 1998-02-20 2005-03-01 Commissariat A L'energie Atomique Procedimiento de seleccion de tumores que expresan hla-g sensibles a un tratamiento anticanceroso y sus aplicaciones.
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
EP1245675A1 (en) * 2001-03-28 2002-10-02 Kohji Egawa Cancer cell-specific HLA-F antigen and a diagnostic method of cancer by using thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1110556C (zh) * 1993-03-26 2003-06-04 路德维格癌症研究所 编码肿瘤排斥抗原前体mage－3的分离的核酸分子及其应用
CN100381173C (zh) * 2003-03-04 2008-04-16 格林维尔医院系统公司 包含靶向部分和触发免疫反应部分的抗肿瘤剂

Also Published As

Publication number Publication date
HUT67859A (en) 1995-03-23
FI930976L (fi) 1993-09-06
KR930019225A (ko) 1993-10-18
JPH05246889A (ja) 1993-09-24
FI930976A0 (fi) 1993-03-04
EP0563627A3 (2) 1994-04-27
CA2090957A1 (en) 1993-09-06
NO930798L (no) 1993-09-06
NO930798D0 (no) 1993-03-04
FI930976A7 (fi) 1993-09-06
HU9300612D0 (en) 1993-05-28
NZ247057A (en) 1995-10-26
AU3398793A (en) 1993-09-09
ZA931558B (en) 1993-09-27
SK15993A3 (en) 1993-10-06
IL104944A0 (en) 1993-07-08
EP0563627A2 (en) 1993-10-06
BR9300764A (pt) 1993-09-28
CZ34293A3 (en) 1994-01-19

Similar Documents

Publication Publication Date Title
CN1277614A (zh) 乳房珠蛋白,一种乳房特异性乳腺癌分泌蛋白
CN1630529A (zh) 用于诊断和治疗b细胞恶性肿瘤的b细胞淋巴瘤特异性抗原
CN1898262A (zh) Il－7融合蛋白
CN1155904A (zh) Lag-3蛋白的可溶性多肽组分；生产方法、治疗组合物、抗独特型抗体
CN1194000A (zh) 增强保护性免疫应答的方法
CN1278865A (zh) 肿瘤特异性抗原,其制备方法以及它们在免疫和诊断中的应用
CN1589902A (zh) 抗－LT－β－R抗体在制备药用组合物中的应用
CN1190991A (zh) 人类趋化因子β－11和人类趋化因子α－1
CN1244807A (zh) 改良疫苗
CN1079400A (zh) 抗肿瘤方法和抗肿瘤剂
CN1148449C (zh) 链球菌毒素c突变体及其使用方法
CN1189483C (zh) 人源化抗cd3单克隆抗体
CN1929855A (zh) 诱导或调节免疫反应的方法
CN1219881A (zh) 山羊关节炎－脑炎病毒提供抗hiv－1感染的免疫保护
CN1273485C (zh) 新型人树突状细胞来源的免疫球蛋白样受体，其编码序列及用途
CN1251610A (zh) 新型小鼠cxc趋化因子受体
CN1258537C (zh) 制备在去污剂不存在下可溶于含水溶剂的多肽的方法
HK1076026A (en) Human mast cell-expressed membrane proteins
CN1315448A (zh) 一种新的多肽——人微球蛋白转录调控因子30和编码这种多肽的多核苷酸
CN1920026A (zh) 人hMnk2基因序列、其编码蛋白及制备方法
CN1314376A (zh) 一种新的多肽——人凝血因子ix－10和编码这种多肽的多核苷酸
CN1626550A (zh) 作为肿瘤标志物的肿瘤相关分泌蛋白及其用途
CN1393549A (zh) 一种多肽——胰蛋白酶原－26.51和编码这种多肽的多核苷酸
CN1278003A (zh) 一种人亚精胺/精胺乙酰基转移酶蛋白异构体及其编码序列
CN1363669A (zh) 一种新的多肽——核糖基转移酶32.23和编码这种多肽的多核苷酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication